How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Cutaneous Squamous Cell Carcinoma Is a Spectrum of Disease

Case 1 Harriet

Case 1 Harriet (cont)

What Is Locally Advanced cSCC?

Staging cSCC

High-Risk cSCC

Widespread Local cSCC Is High-Risk

Widespread Local cSCC Is High-Risk (cont)

Widespread Local cSCC Is High-Risk (cont)

Treatment of Advanced cSCC

Cetuximab First-Line Monotherapy in cSCC

Postoperative ChemoRT vs RT in cSCC

Case 2 Dominic

Case 2 Dominic (cont)

Who Would Be a Candidate for Immunotherapy?

Case 2 Dominic (cont)

Phase 2 Study of Pembrolizumab in Metastatic cSCC Study Design

Phase 2 Study of Pembrolizumab in Metastatic cSCC Results

Phase 2 Study of Cemiplimab in Metastatic cSCC Study Design

Phase 2 Study of Cemiplimab in Metastatic cSCC Results

Phase 2 Study of Cemiplimab in Metastatic cSCC Safety Data

Cemiplimab in cSCC Phase 1 Expansion Cohorts

Interpretation of Emerging Data

Question & Answer Session

Q&A

Q&A (cont)

Q&A (cont)

Q&A (cont)

Conclusions and Key Takeaways

Abbreviations

Abbreviations (cont)